News:Research and scientific results

The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.

A study led by the BBRC has found that people without cognitive problems but with a higher genetic risk of developing Alzheimer's have certain areas of the brain more resilient to the disease if they are accustomed to consuming a nutrient provided by blue fish.

A team of researchers from the AMYPAD consortium, led at BBRC, showed that the visual assessment used in clinical practice to evaluate amyloid PET images is sensitive to detecting the earliest stages of Alzheimer’s disease, and suggests a method to classify the extent of the pathology in the brain.

Investigators at the CNIC, in partnership with the BBRC, have discovered a link between brain metabolism, cardiovascular risk, and atherosclerosis during middle age, years before symptoms appear

The scientific publications of the promoter of the BBRC Alzheimer's Prevention Program are among the 1% of the most cited in its field in Web of Science.

An international team of researchers, led at the BBRC, has discovered that a series of biomarkers recently described to detect the most advanced phase of Alzheimer's can also detect the preclinical phase of the disease in the cerebrospinal fluid and plasma.

The digitization of the data collected in our studies allows us to accelerate our research, improve its integrity and make it available to researchers around the world.

Discover #undíaparaolvidar

Dr José Luis Molinuevo comments the possible approval of Biogen’s new treatment, in an interview for the podcast Saving Minds.